AAAAAA

   
Results: 1-25 | 26-50 | 51-58
Results: 26-50/58
OPTIMAL SAMPLING STRATEGIES FOR BAYESIAN-ESTIMATION OF DOCETAXEL (TAXOTERE) CLEARANCE
Authors: BAILLE P BRUNO R SCHELLENS JHM WEBSTER LK MILLWARD M VERWEIJ J MONTAY G
Citation: P. Baille et al., OPTIMAL SAMPLING STRATEGIES FOR BAYESIAN-ESTIMATION OF DOCETAXEL (TAXOTERE) CLEARANCE, Clinical cancer research, 3(9), 1997, pp. 1535-1538
PHASE-I AND PHARMACOLOGICAL STUDY OF DOCETAXEL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: PRONK LC SCHELLENS JHM PLANTING AST VANDENBENT MJ HILKENS PHE VANDERBURG MEL DEBOERDENNERT M MA J BLANC C HARTEVELD M BRUNO R STOTER G VERWEIJ J
Citation: Lc. Pronk et al., PHASE-I AND PHARMACOLOGICAL STUDY OF DOCETAXEL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS, Journal of clinical oncology, 15(3), 1997, pp. 1071-1079
PHASE-I AND PHARMACOLOGICAL STUDY OF ORAL TOPOTECAN ADMINISTERED TWICE-DAILY FOR 21 DAYS TO ADULT PATIENTS WITH SOLID TUMORS
Authors: CREEMERS GJ GERRITS CJH ECKARDT JR SCHELLENS JHM BURRIS HA PLANTING AST RODRIGUEZ GI LOOS WJ HUDSON I BROOM C VERWEIJ J VONHOFF DD
Citation: Gj. Creemers et al., PHASE-I AND PHARMACOLOGICAL STUDY OF ORAL TOPOTECAN ADMINISTERED TWICE-DAILY FOR 21 DAYS TO ADULT PATIENTS WITH SOLID TUMORS, Journal of clinical oncology, 15(3), 1997, pp. 1087-1093
PHARMACOKINETICS OF THE MULTIDRUG-RESISTANCE-CONVERTING DRUG DEXNIGULDIPINE AND ITS PYRIDINE METABOLITE M-1 IN THE PLASMA, TUMOR, AND RENALTISSUE OF TUMOR-BEARING WAG RIJ RATS/
Authors: SCHELLENS JHM VANDEVRIE W LOOS WJ KOLKER HJ VERWEIJ J STOTER G DURANTE NMC EGGERMONT AMM
Citation: Jhm. Schellens et al., PHARMACOKINETICS OF THE MULTIDRUG-RESISTANCE-CONVERTING DRUG DEXNIGULDIPINE AND ITS PYRIDINE METABOLITE M-1 IN THE PLASMA, TUMOR, AND RENALTISSUE OF TUMOR-BEARING WAG RIJ RATS/, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 48-52
CISPLATIN RESISTANCE AND DNA-REPAIR
Authors: CRUL M SCHELLENS JHM BEIJNEN JH MALIEPAARD M
Citation: M. Crul et al., CISPLATIN RESISTANCE AND DNA-REPAIR, Cancer treatment reviews, 23(5-6), 1997, pp. 341-366
IMPROVED P-32 POSTLABELING ASSAY FOR THE QUANTIFICATION OF THE MAJOR PLATINUM-DNA ADDUCTS
Authors: WELTERS MJP MALIEPAARD M JACOBSBERGMANS AJ BAAN RA SCHELLENS JHM MA JG VANDERVIJGH WJF BRAAKHUIS BJM FICHTINGERSCHEPMAN AMJ
Citation: Mjp. Welters et al., IMPROVED P-32 POSTLABELING ASSAY FOR THE QUANTIFICATION OF THE MAJOR PLATINUM-DNA ADDUCTS, Carcinogenesis, 18(9), 1997, pp. 1767-1774
THE BIOAVAILABILITY OF ORAL GI147211 (GG211), A NEW TOPOISOMERASE-I INHIBITOR
Authors: GERRITS CJH SCHELLENS JHM CREEMERS GJ WISSEL P PLANTING AST PRITCHARD JF DEPEE S DEBOERDENNERT M HARTEVELD M VERWEIJ J
Citation: Cjh. Gerrits et al., THE BIOAVAILABILITY OF ORAL GI147211 (GG211), A NEW TOPOISOMERASE-I INHIBITOR, British Journal of Cancer, 76(7), 1997, pp. 946-951
TOPOISOMERASE-I INHIBITORS - THE RELEVANCE OF PROLONGED EXPOSURE FOR PRESENT CLINICAL DEVELOPMENT
Authors: GERRITS CJH DEJONGE MJA SCHELLENS JHM STOTER G VERWEIJ J
Citation: Cjh. Gerrits et al., TOPOISOMERASE-I INHIBITORS - THE RELEVANCE OF PROLONGED EXPOSURE FOR PRESENT CLINICAL DEVELOPMENT, British Journal of Cancer, 76(7), 1997, pp. 952-962
SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC FLUORESCENCE ASSAY FOR THE QUANTITATION OF TOPOTECAN (SKF 104864-A) AND ITS LACTONE RING-OPENED PRODUCT (HYDROXY ACID) IN HUMAN PLASMA AND URINE
Authors: LOOS WJ STOTER G VERWEIJ J SCHELLENS JHM
Citation: Wj. Loos et al., SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC FLUORESCENCE ASSAY FOR THE QUANTITATION OF TOPOTECAN (SKF 104864-A) AND ITS LACTONE RING-OPENED PRODUCT (HYDROXY ACID) IN HUMAN PLASMA AND URINE, Journal of chromatography B. Biomedical applications, 678(2), 1996, pp. 309-315
PHASE-II STUDY OF A SHORT-COURSE OF WEEKLY HIGH-DOSE CISPLATIN COMBINED WITH LONG-TERM ORAL ETOPOSIDE IN METASTATIC MALIGNANT-MELANOMA
Authors: PLANTING AST VANDERBURG MEL GOEY SH SCHELLENS JHM VECHT C DEBOERDENNERT M STOTER G VERWEIJ J
Citation: Ast. Planting et al., PHASE-II STUDY OF A SHORT-COURSE OF WEEKLY HIGH-DOSE CISPLATIN COMBINED WITH LONG-TERM ORAL ETOPOSIDE IN METASTATIC MALIGNANT-MELANOMA, European journal of cancer, 32A(11), 1996, pp. 2026-2028
PHASE-II AND PHARMACOLOGICAL STUDY OF TOPOTECAN ADMINISTERED AS A 21-DAY CONTINUOUS-INFUSION TO PATIENTS WITH COLORECTAL-CANCER
Authors: CREEMERS GJ GERRITS CJH SCHELLENS JHM PLANTING AST VANDERBURG MEL VANBEURDEN VM DEBOERDENNERT M HARTEVELD M LOOS W HUDSON I STOTER G VERWEIJ J
Citation: Gj. Creemers et al., PHASE-II AND PHARMACOLOGICAL STUDY OF TOPOTECAN ADMINISTERED AS A 21-DAY CONTINUOUS-INFUSION TO PATIENTS WITH COLORECTAL-CANCER, Journal of clinical oncology, 14(9), 1996, pp. 2540-2545
COMPARISON OF ETHANOL PLASMA-PROTEIN PRECIPITATION WITH PLASMA ULTRAFILTRATION AND TRICHLOROACETIC-ACID PROTEIN PRECIPITATION FOR THE MEASUREMENT OF UNBOUND PLATINUM CONCENTRATIONS
Authors: MA JG STOTER G VERWEIJ J SCHELLENS JHM
Citation: Jg. Ma et al., COMPARISON OF ETHANOL PLASMA-PROTEIN PRECIPITATION WITH PLASMA ULTRAFILTRATION AND TRICHLOROACETIC-ACID PROTEIN PRECIPITATION FOR THE MEASUREMENT OF UNBOUND PLATINUM CONCENTRATIONS, Cancer chemotherapy and pharmacology, 38(4), 1996, pp. 391-394
PHARMACOKINETICS AND PHARMACODYNAMICS OF TOPOTECAN GIVEN ON A DAILY-TIMES-5-SCHEDULE IN PHASE-II CLINICAL-TRIALS USING A LIMITED-SAMPLING PROCEDURE
Authors: VANWARMERDAM LJC CREEMERS GJ RODENHUIS S ROSING H DEBOERDENNERT M SCHELLENS JHM HUININK WWT DAVIES BE MAES RAA VERWEIJ J BEIJNEN JH
Citation: Ljc. Vanwarmerdam et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF TOPOTECAN GIVEN ON A DAILY-TIMES-5-SCHEDULE IN PHASE-II CLINICAL-TRIALS USING A LIMITED-SAMPLING PROCEDURE, Cancer chemotherapy and pharmacology, 38(3), 1996, pp. 254-260
DOCETAXEL AND PACLITAXES INHIBIT DNA ADDUCT FORMATION AND INTRACELLULAR ACCUMULATION OF CISPLATIN IN HUMAN-LEUKOCYTES
Authors: MA JG VERWEIJ J PLANTING AST KOLKER HJ LOOS WJ DEBOERDENNERT M VANDERBURG MEL STOTER G SCHELLENS JHM
Citation: Jg. Ma et al., DOCETAXEL AND PACLITAXES INHIBIT DNA ADDUCT FORMATION AND INTRACELLULAR ACCUMULATION OF CISPLATIN IN HUMAN-LEUKOCYTES, Cancer chemotherapy and pharmacology, 37(4), 1996, pp. 382-384
MODULATION OF MULTIDRUG-RESISTANCE WITH DEXNIGULDIPINE HYDROCHLORIDE (B8509-035) IN THE CC531 RAT COLON-CARCINOMA MODEL
Authors: VANDEVRIE W SCHELLENS JHM LOOS WJ KOLKER HJ VERWEY J STOTER G DURANTE NMC EGGERMONT AMM
Citation: W. Vandevrie et al., MODULATION OF MULTIDRUG-RESISTANCE WITH DEXNIGULDIPINE HYDROCHLORIDE (B8509-035) IN THE CC531 RAT COLON-CARCINOMA MODEL, Journal of cancer research and clinical oncology, 122(7), 1996, pp. 403-408
PCV-CHEMOTHERAPY IN RECURRENT OLIGODENDROGLIOMA - FACTORS OF PROGNOSTIC-SIGNIFICANCE
Authors: VANDENBENT MJ KROS JM SCHELLENS JHM KROUWER HGJ ZONNEBERG BA HEIMANS JJ VONGROENINGEN CJ BOOGERD W TIJSSEN CC TWIJNSTRA A
Citation: Mj. Vandenbent et al., PCV-CHEMOTHERAPY IN RECURRENT OLIGODENDROGLIOMA - FACTORS OF PROGNOSTIC-SIGNIFICANCE, Neurology, 46(2), 1996, pp. 2038-2038
EMERGING DRUG TREATMENTS FOR SOLID TUMORS
Authors: SCHELLENS JHM PRONK LC VERWEIJ J
Citation: Jhm. Schellens et al., EMERGING DRUG TREATMENTS FOR SOLID TUMORS, Drugs, 51(1), 1996, pp. 45-72
PHARMACOKINETIC PROFILE AND CLINICAL EFFICACY OF A ONCE-DAILY ONDANSETRON SUPPOSITORY IN CYCLOPHOSPHAMIDE-INDUCED EMESIS - A DOUBLE-BLIND COMPARATIVE-STUDY WITH ONDANSETRON TABLETS
Authors: DEWIT R BEIJNEN JH VANTELLINGEN O SCHELLENS JHM DEBOERDENNERT M VERWEIJ J
Citation: R. Dewit et al., PHARMACOKINETIC PROFILE AND CLINICAL EFFICACY OF A ONCE-DAILY ONDANSETRON SUPPOSITORY IN CYCLOPHOSPHAMIDE-INDUCED EMESIS - A DOUBLE-BLIND COMPARATIVE-STUDY WITH ONDANSETRON TABLETS, British Journal of Cancer, 74(2), 1996, pp. 323-326
PHASE-I AND PHARMACOLOGICAL STUDY OF THE NEW TOPOISOMERASE-I INHIBITOR GI147211, USING A DAILY X 5 INTRAVENOUS ADMINISTRATION
Authors: GERRITS CJH CREEMERS GJ SCHELLENS JHM WISSEL P PLANTING AST KUNKA R SELINGER K DEBOERDENNERT M MARIJNEN Y HARTEVELD M VERWEIJ J
Citation: Cjh. Gerrits et al., PHASE-I AND PHARMACOLOGICAL STUDY OF THE NEW TOPOISOMERASE-I INHIBITOR GI147211, USING A DAILY X 5 INTRAVENOUS ADMINISTRATION, British Journal of Cancer, 73(6), 1996, pp. 744-750
RELATIONSHIP BETWEEN THE EXPOSURE TO CISPLATIN, DNA-ADDUCT FORMATION IN LEUKOCYTES AND TUMOR RESPONSE IN PATIENTS WITH SOLID TUMORS
Authors: SCHELLENS JHM MA J PLANTING AST VANDERBURG MEL VANMEERTEN E DEBOERDENNERT M SCHMITZ PIM STOTER G VERWEIJ J
Citation: Jhm. Schellens et al., RELATIONSHIP BETWEEN THE EXPOSURE TO CISPLATIN, DNA-ADDUCT FORMATION IN LEUKOCYTES AND TUMOR RESPONSE IN PATIENTS WITH SOLID TUMORS, British Journal of Cancer, 73(12), 1996, pp. 1569-1575
BIOAVAILABILITY AND PHARMACOKINETICS OF ORAL TOPOTECAN - A NEW TOPOISOMERASE-I INHIBITOR
Authors: SCHELLENS JHM CREEMERS GJ BEIJNEN JH ROSING H DEBOERDENNERT M MCDONALD M DAVIES E VERWEIJ J
Citation: Jhm. Schellens et al., BIOAVAILABILITY AND PHARMACOKINETICS OF ORAL TOPOTECAN - A NEW TOPOISOMERASE-I INHIBITOR, British Journal of Cancer, 73(10), 1996, pp. 1268-1271
PHASE-II STUDY WITH TOPOTECAN (T) ADMINISTERED AS A 21-DAYS CONTINUOUS-INFUSION TO PATIENTS WITH COLORECTAL-CANCER
Authors: CREEMERS GJ GERRITS CHJ PLANTING AST SCHELLENS JHM VANDERBURG MEL DEBOERDENNERT M HARTEVELD M HUDSON I STOTER G VERWEIJI J
Citation: Gj. Creemers et al., PHASE-II STUDY WITH TOPOTECAN (T) ADMINISTERED AS A 21-DAYS CONTINUOUS-INFUSION TO PATIENTS WITH COLORECTAL-CANCER, European journal of cancer, 31A, 1995, pp. 700-700
PHARMACOKINETICS (PK), CLINICAL PHARMACODYNAMICS (PD) AND SAFETY OF CHRONIC ORAL TOPOTECAN (T), IN A PHASE-I STUDY
Authors: SCHELLENS JHM ECKARDT JR VONHOFF DD CREEMERS GJ GERRITS C LOOS WJ HUDSON I BROOM C DAVIES BE VERWEIJ J
Citation: Jhm. Schellens et al., PHARMACOKINETICS (PK), CLINICAL PHARMACODYNAMICS (PD) AND SAFETY OF CHRONIC ORAL TOPOTECAN (T), IN A PHASE-I STUDY, European journal of cancer, 31A, 1995, pp. 926-926
PHASE-II STUDY OF A SHORT-COURSE OF WEEKLY HIGH-DOSE CISPLATIN COMBINED WITH LONG-TERM ORAL ETOPOSIDE IN PLEURAL MESOTHELIOMA
Authors: PLANTING AST VANDERBURG MEL GOEY SH SCHELLENS JHM VANDENBENT MJ DEBOERDENNERT M STOTER G VERWEIJ J
Citation: Ast. Planting et al., PHASE-II STUDY OF A SHORT-COURSE OF WEEKLY HIGH-DOSE CISPLATIN COMBINED WITH LONG-TERM ORAL ETOPOSIDE IN PLEURAL MESOTHELIOMA, Annals of oncology, 6(6), 1995, pp. 613-615
PHARMACOKINETICS AND PHARMACODYNAMICS OF TOPOTECAN ADMINISTERED DAILYFOR 5 DAYS EVERY 3 WEEKS
Authors: VANWARMERDAM LJC VERWEIJ J SCHELLENS JHM ROSING H DAVIES BE DEBOERDENNERT M MAES RAA BEIJNEN JH
Citation: Ljc. Vanwarmerdam et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF TOPOTECAN ADMINISTERED DAILYFOR 5 DAYS EVERY 3 WEEKS, Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 237-245
Risultati: 1-25 | 26-50 | 51-58